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While it is generally accepted that Subcutaneous Injection Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT) are
both eﬃcacious, there is not yet a signiﬁcant amount of information regarding their comparative eﬃcacy. In this paper, we
performed a retrospective chart review and compared treatment results in two groups of patients (both with nasal allergies with
or without asthma) that were treated either with SCIT or SLIT. Both treatment modalities were found to be of similar eﬃcacy.
1.Introduction
Allergicdiseaseisanincreasinglyprevalentproblemaﬀecting
up to one-third of the general population in industrialized
countries. Immunotherapy is a treatment modality that can
modify the immunological response of the allergy suﬀerer
so that the aﬀected individual will stop reacting to involved
allergens. Immunotherapy is indicated for the treatment of
allergic rhinitis (AR) and asthma [1], and it may prevent
development of asthma in patients with AR [1, 2].
Immunotherapy can be administered by diﬀerent routes
amongst which we ﬁnd injectable and oral vaccines. Inject-
able vaccines refers to the classical subcutaneous injection
immunotherapy (SCIT) usually known as “allergy shots.”
Oral vaccines refer to sublingual immunotherapy (SLIT)
where the allergens are administered as drops to the sublin-
gualareaeventhoughthetermoralvaccinesmayalsoinclude
allergy tablets [3].
The purpose of this study is to compare the eﬃcacy of
treatment results in patients with nasal allergies, with or
without asthma, that were treated with either one or the
other of these two treatment modalities: SCIT or SLIT.
There is a voluminous body of scientiﬁc evidence that
proves that these two treatment modalities are eﬃcacious for
the management of allergic conditions but the issue of these
two modalities having similar eﬃcacy has not yet been fully
addressed.Areviewoftheliteraturerevealsonlyafewarticles
that directly address this issue [4–10]. In ﬁve of these reports
[5–9] SCIT and SLIT are found to be equally eﬀective. In one
report[4]SCITisfoundtohavebetterresults,andonereport
[10] ﬁnds both equally eﬀective for AR patients but SCIT
more eﬀective for asthmatic patients. In our own experience,
SLIT and SCIT appear to be of similar eﬃcacy [11] In this
report the eﬃcacy of one will be compared against the other.
SCIT is a well-established treatment modality that has
been successfully used for many decades and is relatively well
tolerated. Occasionally patients can develop severe reactions
that very rarely can result in mortality [12].
SLIT is also a very old treatment modality (earliest
description is from 1900) and yet, while commonly used in
Europe, it is still not well established in the USA [13]. Over
the last 20 years the European medical community produced
a large amount of high-quality evidence suggesting that SLIT
is safer than SCIT [14, 15]. While no single case of mortality
h a se v e rb e e nr e p o r t e dw i t hS L I T[ 12, 16] this is not the case
withSCIT[17,18].SLITissosafeandeasytoadministerthat
patients treat themselves at home [19].
2. Methods
This study constitutes a retrospective, consecutive chart
review of allergy patients treated by the author at his private
oﬃce. The charts of active patients were alphabetically
reviewed to determine eligibility. Inclusion criteria were as
follows: a patient of any age with nasal allergies with or
without asthma that was treated with immunotherapy for at2 Journal of Environmental and Public Health
least for 6 months and had at least 2 complete evaluations.
A complete evaluation implies symptom scoring, evaluation
of medication use, and determination of the peak ﬂow
meter (PFM) value. These evaluations are done every 3–6
months as treatment progresses. Because evaluations depend
on patient’s cooperation not all the patients had the same
number of evaluations, but any patient that was considered
a candidate had to have 2 evaluations as a minimum. We
compared the ﬁrst evaluation (pretreatment) and the last
evaluation the patient had just at the time of inclusion for
the study. These were considered pretreatment and post-
treatment evaluations. The symptoms in the pretreatment
evaluation and the amount of medications the patient was
taking at that time reﬂect how the patient was doing without
immunotherapy treatment.
Ethical Considerations. Subjects’ privacy was respected by
collecting and recording data in such a way that the subjects
could not be identiﬁed, directly or indirectly, through
identiﬁers linked to the subject. In other words, a patient’s
conﬁdentiality would be protected by entering data in a
simple spreadsheet with nonspeciﬁc identiﬁers as patient no.
1, patient no. 2, and so forth with subsequent reﬁling of the
patient’s chart, according to usual procedure. The content of
the spread sheet became anonymous and ready for statistical
analysis.
2.1. Decision to Use SCIT or SLIT. After discussing with
patient about their allergies and advising about environmen-
tal modiﬁcation maneuvers a discussion about treatment
options including immunotherapy follows. In our oﬃce
SCIT or SLIT is used to treat patients with inhalant allergies
with or without bronchial involvement. The decision to use
one or the other is sometimes made by the patient, some-
times advised by the treating physician. Economical consid-
erations, living far from the oﬃce, busy schedule, or “needle
phobia,” are examples of when a patient may chose SLIT.
Having severe asthma, being a very young patient or having
medical problems that may render administration of SCIT
risky are examples of why the treating physician will advise
SLIT.
2.2. Testing and Treatment Administration. All patients were
tested using a ﬁvefold intradermal dilution skin test (IDT)
as taught by the AAOA [20, 21]. The test includes several
panels: dust, dander, epidermals, molds, and pollens for our
geographic area (Table 1).
Standardized antigens were used for testing and treat-
ment whenever these were available; otherwise weight/vol-
ume antigen extracts were used [22].
After identifying the minimally reactive antigen concen-
tration(meaningﬁrstreactivewheal)foreachofthepatient’s
reactiveallergens,SCIT vialsorSLIT bottleswereformulated
including all of the positive results (reactive allergens in the
intradermal test) in the treatment mixture. Patients on SCIT
were treated according to AAOA guidelines [21, 23]. Patients
on SLIT were treated according to a previously published
protocol [11] where the dose is slowly advanced from 1
drop per day to 5 drops per day until attaining the most
concentrated mixture in the SLIT bottle. The formulation
was the same for both injectable and oral vaccines.
2.3. Amount of Antigen Delivered. While the concentration
of antigens is exactly the same for both SCIT and SLIT but
SLIT is administered daily [11], patients on SLIT will receive
a larger amount of antigen each week than those treated
with SCIT. The injectable vials are mixed with a volume
of 5.0mL. The SLIT bottles are mixed with 7.5mL. If we
consider a single allergen, for example, Dermatophagoides
pteronyssinus (DP), standardized dust mite DP has a concen-
tration of 10,000AU/mL containing 68mcg/mL of Der p 1
a n d7 1m c g / m Lo fD e rp2a n t i g e n s[ 22]. If the minimally
reactive antigen concentration occurred at dilution no. 3 and
dose was advanced until mixing a vial from manufacturer’s
concentrate, the cumulative dose this patient would receive
weekly by SCIT would be 200AU per week, while a patient
treated by SLIT would receive 464AU per week [11]. As
stated before, the initial allergen concentration in both SCIT
and SLIT is the same: 80AU/mL as in both circumstances
the extract (with 10.000AU/mL) will be diluted 125 times.
AfteroneyearoftreatmentthepatientonSCITwouldreceive
9680AU and the patient treated by SLIT would receive
21149AU or 2.18 times more allergen [11].
2.4. Sample Comparison in reference to Allergen Reactivity. A
chi-square test was applied for the following allergens: dust
mite, cat, roach, mold, tree-pollens, grass-pollens, and weed-
pollens for both groups, SCIT and SLIT.
2.5. Asthma Diagnosis. Asthma diagnosis was based on the
presence of recurrent cough, chest tightness, SOB, or wheez-
ing [24], having a spirometry consistent with airﬂow ob-
struction or having the symptoms respond to the adminis-
tration of a short-acting broncho-agonist (SABA).
2.6. Scoring. Recorded symptoms included runny nose,
sneezing, nasal obstruction, itchy eyes, itchy ears, cough,
shortness, and wheezing. These were scored according to
Fell’s method [25] with a numerical analog from 0 through 3
as follows:
0 = symptom not present,
1 = symptom is mild,
2 = symptom is moderate,
3 = symptom is severe.
Medicationusewasalsoevaluatedonasimilarnumerical
scale as follows:
0 = medication is not being used,
1 = medication is being used once a week or less,
2 = medication is being used 2–3 times per week,
3 = medication is being used 4 or more times per
week.Journal of Environmental and Public Health 3
Table 1: Allergy test panels.
Dust, dander. and epidermals Molds Trees Grasses Weeds
Mite pteronyssinus Alternaria Ash Bermuda Cocklebur
Mite farinae Aspergillus Beech Johnson English Plantain
Dog Cladosporium Birch Timothy Goldenrod
Cat Curvularia Box Elder Lambs Quarters
Roach americana Epicoccum Elm Pigweed
Roach germanica Fusarium Hickory Ragweed
Helminthosporium Oak Sagebrush
Mucor Sycamore Sheep Sorrel
Penicillium
Pullularia
Table 2: Symptom Results.
Symptom No. of patients Before (mean) After (mean) P value of t-test Signiﬁcance of SCIT/SLIT × before/after interaction
Runny nose SCIT 47 2.1 0.7 <0.001 Not signiﬁcant
Runny nose SLIT 34 1.8 0.5 <0.001
Sneezing SCIT 47 2.0 0.8 <0.001 Not signiﬁcant
Sneezing SLIT 39 1.9 0.8 <0.001
Nasal obstruction SCIT 48 2.4 0.8 <0.001 Not signiﬁcant
Nasal obstruction SLIT 40 2.2 0.9 <0.001
Itchy ears SCIT 38 1.5 0.5 <0.001 Not signiﬁcant
Itchy ears SLIT 30 1.3 0.5 <0.001
Itchy eyes SCIT 46 1.9 0.7 <0.001 Not signiﬁcant
Itchy eyes SLIT 37 1.8 0.7 <0.001
Cough SCIT 46 1.7 0.4 <0.001 Greater improvement for SCIT (P = 0.037)
Cough SLIT 30 1.2 0.4 <0.001
SOB SCIT 6 1.4 0.5 0.041 Not signiﬁcant
SOB SLIT 9 2.0 0.8 0.005
Wheezing SCIT 4 1.3 0.5 0.042 Greater improvement for SLIT. (P = 0.024)
Wheezing SLIT 7 2.5 0.3 0.001
Medications were generically grouped as allergy pills, in-
tranasal steroids (INSs), and short-acting broncho-agonists
(SABAs) in the case of asthmatic patients.
The value of the PFM determination was used as the
parameter to be recorded at each patient’s encounter.
3. Results
Ninety-three charts met the inclusion criteria, 50 on SCIT
and 43 on SLIT. Among the 50 patient’s on SCIT, 20 (40%)
were male, 30 (60%) female ranging in age from 2.33 to 75
years (mean 45 ± 1 7 . 8S D ) .T h i sc o m p a r e dt o4 3p a t i e n t so n
SLIT of whom 21 (49%) were male, 22 (51%) female ranging
in age from 1.66 to 75 years (mean 35 ± 20.8 SD). There are
no statistical diﬀerences between the demographics of both
groups. Analysis of covariance for the dependent variables
for which a signiﬁcant pre/posttreatment by treatment
modality interaction eﬀects was obtained did not reveal
gender or age to account for signiﬁcant dependent variable
variance; in other words the results were not aﬀected by age
or gender so both groups can be considered homogeneous.
Both groups were also compared in reference to test results.
A chi-square test was applied for the following allergens:
dust mite, cat, roach, mold, tree-pollens, grass-pollens, and
weed-pollens. Results indicate that there are no statistical
diﬀerences between both groups (at the P<0.05 level);
therefore in their reactivity to allergens both groups can also
be considered homogeneous.
There were 3 children <12 years on SCIT (mean 7.8
years) versus 11 on SLIT (mean 6.9 years). Ten (20%) SCIT
patients had asthma versus 12 (28%) on SLIT. Thus a greater
percentage of asthmatics (12/22 or 55%) and more children
under12yearsofage(11/14or79%)wereonSLIT.Lengthof
treatment for the SCIT group was 12 to 86 (mean 31 ± 18.7
SD) months and for the SLIT group was 10 to 32 (mean 19 ±
6.3 SD) months.
For all patients the pre- and posttreatment averages for
each symptom, medication use, and PF value were statisti-
cally compared through the use of repeated measure analysis
of variance (ANOVA). The results for the two treatment
modalities (SCIT versus SLIT) were also compared using the
between-subjects factor of the ANOVA (Table 2). The same
analyses were completed for medication use (Table 3). For
the PF evaluation the pre- and post-treatment values were
compared (Table 4).4 Journal of Environmental and Public Health
Table 3: Medication use.
Medication no. of patients Before (mean) After (mean) P-value of t-test Signiﬁcance of SCIT/SLIT × before/after interaction
Pills in SCIT 37 2.0 0.5 <0.001 Not signiﬁcant
Pills in SLIT 25 1.5 0.4 <0.001
INS in SCIT 28 1.5 0.3 <0.001 Not signiﬁcant
INS in SLIT 26 1.2 0.2 <0.001
SABA in SCIT 6 1.6 0.9 0.047 Not signiﬁcant
SABA in SLIT 9 1.1 0.2 0.010
Table 4: Peak Flow Meter determinations. (L/m = litters per minute).
PFM (L/m) no. of patients Before (mean) After (mean) P-value of t-test Signiﬁcance of SCIT/SLIT × before/after interaction
PFM in SCIT 44 368 467 <0.001 Not signiﬁcant
PFM in SLIT 36 323 422 <0.001
3.1. Symptom Results. In Table 2 the mean value for each
symptom score before treatment and at the time of data
collection is shown for both treatment modalities. The result
of the test of signiﬁcance is shown for each symptom within
each treatment modality (paired t-test). Lastly, the result
of the statistical analysis comparing symptom improvement
with one or the other treatment modality is shown.
All symptoms had signiﬁcant improvement with both
treatment modalities. Shortness of breath and wheezing had
signiﬁcant improvements at P<0.05 for both treatment
modalities. The remaining symptoms had a signiﬁcant im-
provement at P<0.001 for both treatment modalities.
Wheezing and coughing were the only symptom scores
which seemed to respond better to either SCIT (coughing
slightly better, P = 0.037) or SLIT (wheezing slightly better,
P = 0.024), though both symptoms signiﬁcantly improved
regardless of treatment modality. For the remaining symp-
toms there was no signiﬁcant diﬀerence between both treat-
ment modalities.
3.2. Results of Medication Use. Both SCIT and SLIT provided
equally signiﬁcant reduction in use of medication (P<
0.001) including allergy pills, INS, and, to a slightly lesser
but still signiﬁcant degree, SABA (Table 3) but without no
signiﬁcant diﬀerence between both treatment modalities.
3.3. Results of Changes in PFM Values. PF value before treat-
mentandatthetimeofthelastpatientevaluationisshownin
Table 4. Both treatment modalities were equally eﬀective in
achieving a signiﬁcant increase in PF values (P<0.001) but
there was no signiﬁcant diﬀerence between both treatment
modalities.
4. Discussion
This paper is a retrospective chart review and as such lacks
the rigor of a prospective randomized study with a placebo
control group which is very diﬃcult to do in a private oﬃce
setting. While an analysis of covariance is useful, it is not
a perfect solution. A future, larger-scale study should be
planned to include the above design characteristics.
We observed that patients usually come to the oﬃce
already using one or more allergy medications. This study,
like others, demonstrates that immunotherapy, whether
SCIT or SLIT, will lead to the reduction of medication use
for AR and/or asthma. It was not the purpose of this paper
toevaluatetheeﬀectofmedicationsonallergysymptomsbut
ratherto comparethe eﬀectsof SCITversusSLITonmedica-
tion use. Both treatment modalities resulted in the reduction
of antihistamines, inhaled nasal steroids, and SABAs.
The slight imbalances in demographic characteristics
between the groups on SCIT versus SLIT were not statis-
tically signiﬁcant and did not aﬀect the statistical results.
The reason why there are more young patients and more
asthmatic patients in the SLIT group can be explained by the
fact that SLIT is safer and easier to administer therefore it
is suggested more frequently for these diﬃcult-to-manage
patients. Indeed we would have expected a much more pro-
nounced diﬀerence; yet fewer than expected chose SLIT
because it is not covered by insurance.
Patients on SCIT have been treated for a longer period of
time because SLIT was added to our practice later than SCIT.
The improvement of the asthmatic symptoms wheezing
and SOB and the decrease in SABA use were signiﬁcant at
P<0.05 yet because of sample size this is not as strong as the
improvement in other symptoms or medications that had an
improvement at the level of P<0.001.
The advantage for SCIT in treating coughing is real,
but the eﬀect size (eta-squared) is only 0.025, meaning that
it only accounts for 2.5% of the variance in pre- versus
posttreatment diﬀerences, which is not much. Therefore, it
can be concluded that SCIT and SLIT exhibit similar eﬃcacy.
The advantage of SLIT in treating wheezing may have been
inﬂuenced by our own bias of suggesting SLIT use to asth-
matic patients as a safer treating modality. It is therefore
more likely that patients with higher symptom scores were
present in the SLIT group.
Our ﬁndings demonstrate that SLIT is not only eﬀective
in controlling symptoms in nasal allergy patients with or
without asthma, in decreasing medication use in such pa-
tients, and in improving parameters of pulmonary function,
but it also appears that SLIT is as eﬀective as SCIT
These ﬁndings are in agreement with those published
in the European literature [26, 27] but certainly this pre-
sentation lacks the scientiﬁc validity of other reports [9]
that present a prospective, randomized, controlled study;Journal of Environmental and Public Health 5
therefore this presentation we hope will serve as a stimulus
for centers with the capability to undertake such a study
to continue with this line of research. This would help the
FDA to ﬁnally recognize SLIT as an eﬀective and safe treat-
ment modality. If SLIT became an FDA-approved treatment
modality (and hopefully) reimbursed by insurance compa-
nies many more patients might be receptive to immunother-
apy which is a treatment capable of altering the immunolog-
ical mechanisms responsible for the development of allergic
conditions [28].
PF values for asthma control should be taken as a
guidelineonlybecausethepredictedlungfunctionhasahigh
degree of variability with signiﬁcant diﬀerences in PF values
according to presence or not of lung disease, smoking, age,
sex, and even patient’s social environment [29–31].
Having the advantage of providing results quickly, and
requiring little training (from the patient as well as from
the technical staﬀ), the PFM device is useful to monitor
progress during immunotherapy [32]. It is most useful when
the changes in PF values are compared to the initial value
of each patient, recorded at the time of treatment initiation
[32]. For the purpose of this study individual improvement
withtherapyis not reported, butratheran overalltrend,thus
the use of PFM provides a gross indicator of change.
Immunotherapy is administered over a long period of
time. Some of our patients were children, and it is expected
they grow during treatment. Certainly using a PFM as a tool
to determine improvement in pulmonary function adds
uncertainty as to whether the improvement in PF value is
related to clinical improvement or to the growth of the pa-
tient during treatment. In this study the number of young
patients was not large. On the other hand we have demon-
strated that the PF value in patients treated by immunother-
apy increases regardless of age or asthmatic condition [32].
In our experience, the use of SLIT with multiple antigens
hasenabledustotreatpatientsthatotherwisewouldhavenot
received immunotherapy, or would have not continued to
receive immunotherapy, like asthmatic patients with poorly
controlled asthma, patients that had severe arm reactions,
very young patients to whom it is diﬃcult to administer
shots or patients whose schedules prevent them from being
compliant.
5. Conclusions
These results suggest that SCIT and SLIT exhibit similar
eﬃcacy. SLIT objectively improves symptom scores for
asthma and AR while decreasing medication usage of allergy
medications and SABAs.
Given the increased risk and diﬃculty in treating asth-
matic and young patients, these results would suggest that
SLIT should be considered as the main treatment modality
for these patients, considering SCIT only for treatment
failures.
The results of this study are in agreement with the Euro-
pean literature and therefore would support the inclusion of
SLIT in the routine management of the allergic disease.
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